Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow INTERPACE BIOSCIENCES, INC.

Get SEC filing alerts via email and in your feed for INTERPACE BIOSCIENCES, INC.

IDXG

INTERPACE BIOSCIENCES, INC.

About INTERPACE BIOSCIENCES, INC.

Interpace Biosciences specializes in esoteric molecular diagnostic testing and pathology services for cancer risk assessment. Its core offerings include genomic tests and assays for gastrointestinal, endocrine, and lung cancers, aiding physicians in diagnosis, risk stratification, and personalized treatment decisions. Serving hospitals, clinics, and labs, the company emphasizes clinical utility, reimbursement support, and innovative research to improve patient outcomes and reduce unnecessary surgeries.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from INTERPACE BIOSCIENCES, INC.

1
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 22% Revenue Decline in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 18% Revenue Decline, Shifts Focus to Thyroid Cancer Diagnostics

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 29% Revenue Decline in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 23% Revenue Decline in Q2 2025 Due to Medicare Reimbursement Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 13% Revenue Growth to $11.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 17% Revenue Growth to $46.9 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
INTERPACE BIOSCIENCES, INC. Interpace Biosciences Reports 35% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments